Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)

BACKGROUND: The current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the treatment burden and improve compliance, is increasing....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Thromb Haemost
Hauptverfasser: Klamroth, Robert, Feistritzer, Clemens, Friedrich, Ute, Lentz, Steven R., Reichwald, Kirsten, Zak, Marek, Chowdary, Pratima
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
HAEMOSTASIS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027501/
https://ncbi.nlm.nih.gov/pubmed/31618804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14660
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge